Xintela AB (OSTO:XINT) EBITDA Margin %: -2,499.77% (As of Mar. 2026)

What is Xintela AB EBITDA Margin %?

Xintela AB OSTO:XINT -6.25% 12 EBITDA Margin % is -2,499.77% as of Mar. 2026. GuruFocus rates OSTO:XINT with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, Xintela AB ranks worse than 84.23% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Xintela AB's EBITDA for the three months ended in Mar. 2026 was kr-11.07 Mil. Xintela AB's Revenue for the three months ended in Mar. 2026 was kr0.44 Mil. Therefore, Xintela AB's EBITDA margin for the quarter that ended in Mar. 2026 was -2,499.77%.

Xintela AB (OSTO:XINT) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Xintela AB EBITDA Margin % Related Terms

Xintela AB EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Xintela AB's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xintela AB EBITDA Margin % Chart

Xintela AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBITDA Margin %

Get a 7-Day Free Trial

0.00

-68,546.15

-922.16

-2,018.62

Xintela AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBITDA Margin %	Get a 7-Day Free Trial															-7,097.86	-1,304.36	-1,088.54	-3,721.69	-2,499.77

OSTO:XINT vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Xintela AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xintela AB EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xintela AB's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Xintela AB's EBITDA Margin % falls into.

Save Embed

12GF Score

Xintela AB OSTO:XINT

EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Xintela AB EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Xintela AB's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-46.065	/	2.282
	=	-2,018.62 %

Xintela AB's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-11.074	/	0.443
	=	-2,499.77 %

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of -2,499.77% mean?

Xintela AB (OSTO:XINT) has a EBITDA Margin % of -2,499.77% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Xintela AB and its competitors. According to the industry distribution chart, Xintela AB ranks #796 out of 945 companies in the Biotechnology industry, placing it in the top 84.2%.

Is Xintela AB's EBITDA Margin % too high?

Xintela AB's current EBITDA Margin % is -2,499.77%. Based on the distribution chart, Xintela AB ranks #796 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Xintela AB has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.

How does Xintela AB's EBITDA Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Xintela AB ranks #796 out of 945 companies for EBITDA Margin %. This places Xintela AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Biotechnology company?

A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Xintela AB and its competitors. Xintela AB's current EBITDA Margin % is -2,499.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Xintela AB stock overvalued right now?

Xintela AB (OSTO:XINT) has a current EBITDA Margin % of -2,499.77%. The current EBITDA Margin % is -2,499.77%. Xintela AB's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Xintela AB (OSTO:XINT), the current EBITDA Margin % is -2,499.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Xintela AB Business Description

Industry Healthcare Biotechnology

Comparable Companies OSTO:INIT OSTO:NICA XSAT:DEX OSTO:XBRANE OSTO:ACTI OSTO:ISOFOL OSTO:ALZCUR OSTO:DMYD B OSTO:ELIC XSAT:ABERA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 1XT:Germany

Address Medicon Village, Lund, SWE, 223 81

Website https://www.xintela.se

Xintela AB is a clinical-stage biopharmaceutical company that develops cutting-edge medical products in stem cell therapy and targeted cancer therapy. Its wholly owned subsidiary, Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin ?10?1. TARG9, an antibody-drug conjugate (ADC), and TARG10, a function-blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers, including triple-negative breast cancer and brain tumor glioblastoma. Xintela has two clinical studies ongoing with the stem cell product XSTEM and EQSTEM.

12GF Score

Get the complete analysis for OSTO:XINT

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.18

Price

View OSTO:XINT Analysis

See EBITDA Margin % data for all stocks →